Michael Stowasser

Michael Stowasser

Website |   Email

University of Queensland School of Medicine
Hypertension Unit
Princess Alexandra Hospital
Ipswich Road, Woolloongabba
Brisbane, QLD, 4102, Australia

T: +61 07 3176 2694
F: +61 07 3176 2969

Michael is Director of the Hypertension Units and of the University of Queensland Endocrine Hypertension Research Centre at Greenslopes and Princess Alexandra Hospitals and current President of the High Blood Pressure Research Council of Australia. He has more than 30 years research experience into various forms of hypertension and especially of endocrine varieties including primary aldosteronism which he helped demonstrate is ~10 times more common than previously thought, and the commonest specifically treatable and potentially curable form of hypertension. Ongoing studies are aimed at exploring the genetic bases and pathogenesis and improving diagnosis and treatment of primary aldosteronism and other hypertensive conditions.


Director, Endocrine Hypertension Research Centre


  • Aldosterone-producing adenoma associated with non-suppressed renin: a case series.
    Jansen PM, Stowasser M.  J Hum Hypertens 2022;36:376-80. [Article]

  • Diagnosis and treatment of primary aldosteronism
    Reincke M, Bancos I, Mulatero P, Scholl UI, Stowasser M, Williams TA. Lancet Diab Endocrinol 2021;9:876-92 [Article]

  • Aldosterone and Primary Aldosteronism: Star Performers in Hypertension Research
    Stowasser M.Hypertension. 2021 Sep;78(3):747-750. doi: 10.1161/HYPERTENSIONAHA.121.17594. Epub 2021 Aug 11.PMID: 34379432 No abstract available. [Article]

  • The Cl-/HCO3- exchanger pendrin is downregulated during oral co-administration of exogenous mineralocorticoid and KCl in patients with primary aldosteronism.
    Wu A, Wolley MJ, Wu Q, Gordon RD, Fenton RA, Stowasser M.  J Hum Hypertens 2021;35:837-48. [Article]

  • The Cl−/HCO3− exchanger pendrin is downregulated during oral co-administration of exogenous mineralocorticoid and KCl in patients with primary aldosteronism
     &  Journal of Human Hypertension (2020) [Article]

  • Effects of Ramipril on the Aldosterone/Renin Ratio and the Aldosterone/Angiotensin II Ratio in Patients With Primary Aldosteronism
    Guo Z, Poglitsch M, Cowley D, Domenig O, McWhinney BC, Ungerer JPJ, Wolley M, Stowasser M. Hypertension. 2020 Jun 8:HYPERTENSIONAHA12014871. doi: 10.1161/HYPERTENSIONAHA.120.14871. Online ahead of print. PMID: 32507039 [Article]

  • Diagnosis of Primary Aldosteronism by Seated Saline Suppression Test-Variability Between Immunoassay and HPLC-MS/M
    Thuzar M, Young K, Ahmed AH, Ward G, Wolley M, Guo Z, Gordon RD, McWhinney BC, Ungerer JP, Stowasser M. J Clin Endocrinol Metab. 2020 Mar 1;105(3):dgz150. doi: 10.1210/clinem/dgz150. PMID: 31676899 [Article]

  • Controversies and advances in adrenal venous sampling in the diagnostic workup of primary aldosteronis
    Wolley M, Thuzar M, Stowasser M. Best Pract Res Clin Endocrinol Metab. 2020 Feb 22:101400. doi: 10.1016/j.beem.2020.101400. Online ahead of print. PMID: 32115358 Review. [Article]

  • The interplay of renal potassium and sodium handling in blood pressure regulation: critical role of the WNK-SPAK-NCC pathway
    Wu A, Wolley M, Stowasser M. J Hum Hypertens. 2019 Jul;33(7):508-523. doi: 10.1038/s41371-019-0170-6. Epub 2019 Feb 5. PMID: 30723251 [Article]

  • Pathogenesis of Familial Hyperaldosteronism Type II: New Concepts Involving Anion Channels
    Stowasser M, Wolley M, Wu A, Gordon RD, Schewe J, Stölting G, Scholl UI. Curr Hypertens Rep. 2019 Apr 4;21(4):31. doi: 10.1007/s11906-019-0934-y. PMID: 30949771 Review. [Article]